# Hims & Hers business expansion and regulatory navigation > Live situation record from CLSTR: https://clstr.news/situations/hims-hers-business-expansion-and-regulatory-navigation > Updated: 2026-09-19T12:00:44.000Z. Sources: 14. Developments: 3. Hims & Hers has pursued international expansion and product diversification while navigating significant regulatory and financial shifts. In August 2026, the telehealth company expanded into Australia following its acquisition of the digital health platform Eucalyptus. This move allowed the company to offer branded GLP-1 weight-loss drugs, sexual health medications, and cholesterol treatments, with plans to introduce a women’s health segment via the brand Juniper. By September 2026, the company reported strong financial performance, with Q2 2026 revenue reaching $753 million, representing a year-over-year increase of approximately 38% to 40%, supported by a subscriber base exceeding 2.5 million. However, this growth occurred alongside intensifying legal and regulatory challenges. In addition to FDA scrutiny regarding compounded GLP-1 drugs—which prompted a strategic pivot toward a direct distribution partnership with Novo Nordisk for branded Ozempic and Wegovy—the company is facing a Federal Trade Commission (FTC) lawsuit. The FTC alleges that Hims & Hers disclosed customer health data, utilized hard-to-cancel subscriptions, and bypassed real-time physician consultations. Hims & Hers has disputed these claims, characterizing the legal action as an attempt to ‘generate headlines at our expense.’ Furthermore, a securities fraud class action lawsuit has been filed against the company, alleging material misstatements regarding its privacy practices. Financial analysts have noted that while the company maintains strong operating momentum, risks remain concerning declining gross margins and the impact of lower-margin weight-loss treatments. ## Claims - The FTC has filed a lawsuit against Hims & Hers alleging deceptive and unethical business practices. (corroborated by 3 sources) - The FTC has previously filed cases against BetterHelp and GoodRx for sharing user health data with Meta and Google without permission. (corroborated by 3 sources) - Hims & Hers disputes the FTC's allegations, characterizing them as an attempt to generate headlines. (corroborated by 3 sources) - Current federal health information laws often do not apply to many telehealth companies. (corroborated by 3 sources) ## Timeline ### 2026-09-19: Hims & Hers faces FTC lawsuit over medical data privacy The FTC is suing telehealth provider Hims & Hers over allegations of deceptive practices, including unauthorized sharing of sensitive medical data and bypassing doctor consultations. 10 sources. https://clstr.news/cluster/ftc-sues-telehealth-provider-hims-hers-over-data-privacy-and-deceptive-practices ### 2026-09-13: Hims & Hers Health navigates regulatory shifts and revenue growth Hims & Hers Health reports strong Q2 2026 revenue growth despite facing FTC privacy lawsuits and FDA regulatory shifts regarding compounded weight-loss drugs. 2 sources. https://clstr.news/cluster/hims-hers-health-navigates-regulatory-shifts-and-revenue-growth ### 2026-08-31: Hims & Hers launches weight-loss and men's health treatments in Australia Hims & Hers has launched GLP-1 weight-loss drugs and men's health treatments in Australia following its acquisition of the digital health platform Eucalyptus. 2 sources. https://clstr.news/cluster/hims-hers-launches-weight-loss-and-mens-health-treatments-in-australia --- Cite as: Hims & Hers business expansion and regulatory navigation. CLSTR, https://clstr.news/situations/hims-hers-business-expansion-and-regulatory-navigation